Actinium Pharmaceuticals (ATNM) Capital Expenditures (2012 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Capital Expenditures of $2000.0 for Q1 2026, down 81.82% quarter-over-quarter from $11000.0 in Q1 2024.
Actinium Pharmaceuticals (ATNM) Capital Expenditures (2012 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Capital Expenditures for 14 consecutive years, with $2000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures changed N/A year-over-year to $2000.0; the TTM figure through Mar 2026 stood at $2000.0 (changed N/A YoY), while the FY2025 annual figure was $104000.0, up 845.45% from the prior year.
- Capital Expenditures fell to $2000.0 in Q1 2026 per ATNM's latest filing, from $11000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $270000.0 in Q2 2022 and bottomed at $2000.0 in Q1 2026.
- Historically, Capital Expenditures has averaged $59111.1 across 4 years, with a median of $30000.0 in 2023.
- Annual changes were most pronounced in 2023 — Capital Expenditures soared 985.71% — and 2024, when it tumbled 85.53%.
- Actinium Pharmaceuticals' Capital Expenditures stood at $16000.0 in 2022, then surged by 87.5% to $30000.0 in 2023, then plunged by 63.33% to $11000.0 in 2024, then slumped by 81.82% to $2000.0 in 2026.
- Business Quant data shows ATNM's Capital Expenditures at $2000.0 in Q1 2026, $11000.0 in Q1 2024, and $30000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | 478,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 478,000.00 |
| Jun 30, 2026 | 478,000.00 |
| Mar 31, 2026 | 2,000.00 |
| Mar 31, 2026 | 2,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Sep 30, 2023 | 30,000.00 |
| Sep 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 47,000.00 |
| Jun 30, 2023 | 47,000.00 |
| Mar 31, 2023 | 76,000.00 |
| Mar 31, 2023 | 76,000.00 |
| Dec 31, 2022 | 16,000.00 |
| Dec 31, 2022 | 16,000.00 |
| Sep 30, 2022 | 73,000.00 |
| Sep 30, 2022 | 73,000.00 |
| Jun 30, 2022 | 270,000.00 |
| Jun 30, 2022 | 270,000.00 |
| Mar 31, 2022 | 7,000.00 |
| Mar 31, 2022 | 7,000.00 |